Arbutus Biopharma Corp 8-K

What Happened

• Arbutus Biopharma filed an 8-K (July 16, 2026) reporting that, on July 15, 2026, it and Genevant Sciences GmbH entered into a Termination Agreement that ends the March 2025 RSV Agreement. Under the Termination Agreement, Genevant will pay Arbutus a $1.0 million termination fee within ten business days.
• The March 2026 global Settlement Agreement among Arbutus, Genevant (and certain Genevant affiliates) and Moderna did not specifically allocate settlement proceeds to Moderna’s RSV vaccine (mRESVIA). The RSV Agreement had provided that Arbutus would be entitled to any award or settlement proceeds specifically allocated to mRESVIA.
• The company also announced (via a July 16, 2026 press release) that Arbutus and Genevant filed three international lawsuits to enforce their lipid nanoparticle (LNP) patents against Pfizer/BioNTech and certain affiliates, and that Arbutus has received its share of a Noncontingent Settlement Payment and expects a dividend from Genevant’s parent in the third quarter of 2026.

Key Details

• Termination Agreement dated July 15, 2026; Genevant to pay Arbutus $1.0 million within 10 business days.
• March 2026 Settlement with Moderna resolved global patent litigation but did not allocate proceeds to mRESVIA.
• Arbutus announced intent to return capital to shareholders via share repurchases of up to approximately $230 million (possible forms: tender offer including a modified Dutch auction, open market, private transactions, accelerated repurchases); repurchases will not begin until after receipt of the expected Genevant Parent dividend.
• The filing includes a Letter Agreement dated July 15, 2026 with Lindsay Androski (Exhibit 10.2) and a press release dated July 16, 2026 (Exhibit 99.1).

Why It Matters

• The Termination Agreement closes the contractual route under the RSV Agreement for allocating any Moderna-related mRESVIA proceeds to Arbutus, in exchange for a $1.0M termination payment.
• Receipt of the Noncontingent Settlement Payment and the expected dividend from Genevant Parent are the near-term cash events cited by Arbutus as enabling a potential return of capital — up to ~$230M in share repurchases — which could reduce share count and return value to shareholders if executed.
• The company’s filing makes clear that any repurchase program is subject to Board approval and receipt of the expected dividend; there is no guarantee the repurchases will occur or occur on the stated timing. The filing also reiterates ongoing litigation and IP enforcement activity (including new suits versus Pfizer/BioNTech), which remain material to the company’s prospects.